NR4A1 and cancer: In a case series of 11780 tumours (Shet et al, 2009) from the largest tertiary care referral centre for the Mumbai Cancer Registry, the investigators reported a redistribution of hormone receptor expression over an 8-year period – ER+ (7.5–10.6%) and ER+/PR+ status (25 to 41.8%) increased between 1999 and 2006 while PR+ decreased (21–3.4%).